Login to Your Account



Financings Roundup

Tokai Adds $35.5M in Series E, Preps for Phase III CRPC Trials

By Jennifer Boggs
Managing Editor

Thursday, May 16, 2013
Development of Tokai Pharmaceuticals Inc.'s triple-acting prostate cancer drug galeterone got a $35.5 million boost, with the Cambridge, Mass.-based biotech closing a Series E round with current investors Apple Tree Partners and Novartis Venture Funds, as well as undisclosed angel investors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription